R&G Pharma announced that on July 1, 2024, the board of directors approved a share repurchase plan, intending to use its own funds to repurchase company shares through centralized bidding transactions for the employee stock ownership plan or equity incentive. As of June 30, 2025, the company had repurchased a total of 1.442 million shares, accounting for approximately 1.49% of the company's total share capital, with a highest transaction price of 43.15 yuan/share and a lowest transaction price of 35.06 yuan/share, totaling a transaction amount of 56.0627 million yuan. This repurchase complies with the company's repurchase plan and relevant laws and regulations, with a repurchase period of 12 months from the date of board approval
